Sweet C S, Ludden C T, Frederick C M, Ribeiro L G
Am J Med. 1984 Aug 20;77(2A):7-12. doi: 10.1016/s0002-9343(84)80052-2.
The effects of enalaprilat (MK-422), an angiotensin converting enzyme inhibitor, were compared to those of SCRIP, a renin inhibitor, in experimentally induced left ventricular failure. In anesthetized dogs, acute left ventricular failure was induced by repeated embolization, via the left main coronary artery, with 50 microns plastic microspheres. Embolization significantly increased left ventricular enddiastolic pressure from 6 +/- 1 to 14 +/- 1 (p less than 0.05) mm Hg and decreased both left ventricular maximal dP/dt (3,135 +/- 338 to 1,636 +/- 126 mm Hg/second, p less than 0.05) and cardiac output (3.0 +/- 0.3 to 1.6 +/- 0.1 liters per minute, p less than 0.05). Embolization also significantly reduced heart rate and mean arterial pressure. These parameters remained stable after induction of heart failure. Forty-five minutes after embolization, 16 dogs received enalaprilat (100 microns/kg intravenously) and six dogs received SCRIP (100 microns/kg intravenously followed by 10 microns/kg per minute). Both agents caused similar reductions in left ventricular end-diastolic pressure (21 percent versus 26 percent) and total peripheral resistance (25 percent versus 32 percent) and rise in peak positive cardiac contractility, as measured by (dP/dt)/P, (12 percent versus 11 percent). The data suggest that inhibition of angiotensin II formation by two agents, each or which acts at a different point in the cascade, results in similar beneficial hemodynamic effects in dogs with acute left ventricular failure. In addition, angiotensin converting enzyme inhibition failed to further increase sodium excretion and glomerular filtration rate caused by embolization. In summary, inhibition of angiotensin II production by two different inhibitors of the renin system causes an improvement in left ventricular performance in a model of acute experimental left ventricular failure.
在实验性诱导的左心室衰竭中,将血管紧张素转换酶抑制剂依那普利拉(MK - 422)的效果与肾素抑制剂SCRIP的效果进行了比较。在麻醉犬中,通过经左主冠状动脉反复注入50微米的塑料微球诱导急性左心室衰竭。注入微球后,左心室舒张末期压力从6±1显著升高至14±1(p<0.05)毫米汞柱,左心室最大dP/dt(从3135±338降至1636±126毫米汞柱/秒,p<0.05)和心输出量(从3.0±0.3降至1.6±0.1升/分钟,p<0.05)均降低。注入微球还显著降低了心率和平均动脉压。心力衰竭诱导后这些参数保持稳定。注入微球45分钟后,16只犬接受依那普利拉(静脉注射100微克/千克),6只犬接受SCRIP(静脉注射100微克/千克,随后以每分钟10微克/千克给药)。两种药物均使左心室舒张末期压力(分别降低21%和26%)和总外周阻力(分别降低25%和32%)出现相似程度的下降,并使通过(dP/dt)/P测量的心脏正性收缩力峰值升高(分别升高12%和11%)。数据表明,两种作用于级联反应不同点的药物对血管紧张素II形成的抑制,在急性左心室衰竭犬中产生了相似的有益血流动力学效应。此外,血管紧张素转换酶抑制未能进一步增加注入微球所致的钠排泄和肾小球滤过率。总之,肾素系统的两种不同抑制剂对血管紧张素II生成的抑制在急性实验性左心室衰竭模型中可改善左心室功能。